retatrutide clinical trial retatrutide drug ⚠️ “RETA” is NOT an approved weight-loss medication. Social media is full of “RETA” offers—but here's what you should know. is a promising investigational medicine developed by Eli Lilly. The Phase Retatrutide Results: 28.3% Weight Loss

Studies have identified erythrose as a metabolite that protected against abdominal aortic calcification (AAC)

When this happens, you may feel dizzy or fatigue

This dual mechanism provides: GLP-1 receptor activation: Enhanced glucose-stimulated insulin secretion, slowed gastric emptying, and increased satiety signaling GIP receptor activation: Additional insulin secretion support and potential effects on lipid metabolism and fat deposition Tirzepatide gained regulatory approval in 2023 and has been extensively studied in Phase 3 clinical trials with larger patient populations and longer durations

Who May Be a Candidate for Tesamorelin